Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Bachelot comments on biomarker findings from breast cancer studies.
He first talks about exploratory results from the PADA-1 study looking at prognostic impact of ESR1 mutations in patients with ER-positive, HER2-negative metastatic breast cancer treated with first-line palbociclib combined with an aromatase inhibitor. Secondly he discusses the results of ctDNA investigation from the pooled analysis of three phase III MONALEESA trials, assessing ribociclib in metastatic breast cancer patients for informing future treatment strategy.
- 1010: Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial - François-Clément Bidard
- 1009: Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials - Fabrice André
This video was supported with an educational grant from Daiichi Sankyo and Novartis. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.